- Home
- LXP vs NAMS Comparison
LXP vs NAMS Comparison
Compare LXP & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LXP | NAMS |
|---|---|---|
| Founded | 1993 | 2019 |
| Country | United States | Netherlands |
| Employees | 58 | 100 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LXP | NAMS |
|---|---|---|
| Price | $52.67 | $38.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $51.88 | $46.75 |
| AVG Volume (30 Days) | 423.5K | ★ 938.9K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.58% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $17.96 |
| Revenue Next Year | $6.00 | $540.65 |
| P/E Ratio | $26.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.64 | $16.79 |
| 52 Week High | $52.79 | $42.00 |
Technical Indicators
Market Signals| Indicator | LXP | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 62.05 | 69.61 |
| Support Level | $48.19 | $34.05 |
| Resistance Level | N/A | $41.40 |
| Average True Range (ATR) | 1.21 | 2.20 |
| MACD | 0.09 | 0.62 |
| Stochastic Oscillator | 96.51 | 77.33 |
Price Performance
Historical ComparisonAbout LXP LXP Industrial Trust (Maryland REIT)
LXP Industrial Trust is a real estate investment trust principally involved in the ownership of equity and debt investments in single-tenant properties and land throughout the United States. The majority of the revenue is earned through rental revenue.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.